Medical/Pharmaceuticals

HZICC:Innovation hub: Hangzhou witness new voices and new ambitions

HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- The remarkable achievements of past winners of Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents have set a powerful example, inspiring a new wave of international innovators to bring their projects toHangzhou. Among this yea...

2025-11-28 21:25 819

HZICC:Unlocked potential: why global innovators choose Hangzhou

HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured let...

2025-11-28 21:19 799

BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough

* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...

2025-11-28 21:00 623

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...

2025-11-28 13:00 863

Keep Your Respiratory Health Strong This Season With VARON Black Friday Offers

NEW YORK, Nov. 27, 2025 /PRNewswire/ -- As the holiday season approaches, respiratory health becomes a top priority for individuals living with chronic conditions such as COPD, sleep apnea, or other lung diseases. VARON,

2025-11-28 06:09 799

Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market

SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...

2025-11-27 22:00 967

SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation

New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...

2025-11-27 10:39 812

TCI Biotech Inaugurates Advanced Performance Nutrition Research Center, Expands Into Brain Science to Accelerate Next-Generation Health Innovation

SALT LAKE CITY, Nov. 26, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a global CDMO+ specializing in functional foods, nutraceuticals, and beauty supplementation, today announced the launch of the TCI Advanced Performance Nutrition Research Center, a new innovation hub focused on high-perfor...

2025-11-27 00:00 747

Healgen Scientific Spotlights the Rapid Check® COVID-19/Flu A&B Antigen Test to Help Families Stay Prepared for the Respiratory Virus Season

HOUSTON, Nov. 26, 2025 /PRNewswire/ -- As the holiday season approaches, gatherings among family and friends are expected to increase the risk of respiratory virus transmission, including COVID-19 and influenza. In response, Healgen® Scientific highlights the Rapid Check® COVID-19/Flu A&B Antigen ...

2025-11-27 00:00 678

Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA®  (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal

* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...

2025-11-26 14:48 1326

Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy

– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's primary endpoint, was -58.54%. Sparsentan was well-t...

2025-11-26 14:00 750

Korea Innovation Foundation selects 2 Innovative bio health companies, LEEBIO, and Airlab for Global Technology Commercialization Support Program (North America)

DAEJEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Korea Innovation Foundation (INNOPOLIS), currently operating the 2025 Global Technology Commercialization Support Program (North America), announces that 2 innovative companies, LEEBIO, and Airlab are chosen for the support program. This initia...

2025-11-26 13:45 709

BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

XI'AN, China, Nov. 25, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co...

2025-11-25 22:41 936

Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911

SHANGHAI, Nov. 25, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug ...

2025-11-25 22:00 837

Neurophet and The Florey Strengthen Research Collaboration on 'Neurophet AQUA' to Advance Alzheimer's Disease Diagnosis

* Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and management * Joint research to enhance dementia diagnosis using the brain neurodegeneration imaging software 'Neurophet AQUA' SEOUL, South Korea, Nov. 25, 2025 /PRNewswire/ -- Neurophet ...

2025-11-25 22:00 1237

Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2025-11-25 17:00 855

HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization

* The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platf...

2025-11-25 00:30 1140

ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- ToolGen Inc. (K...

2025-11-24 22:00 1015

HoneyNaps Accelerates Clinical Trial Pipelines with FDA-Cleared AI "SOMNUM"

* Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time * Joint Clinical Studies with CROs: SOMNUM™ AI Sleep Scoring Drives Higher Efficiency * FDA-cleared AI solution shortens clinical trial timelines while ensuring data reliability * Expanded global partnershi...

2025-11-24 17:24 610

Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial

Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced onNovember 20 that it has administered the f...

2025-11-24 15:11 742
12345 ... 246